Dicaltrol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dicaltrol

Quick Facts

Feature Detail
Active Ingredient Calcitriol (an active form of Vitamin D)
Primary Function Regulation of calcium and phosphate homeostasis
Administration Oral capsule or solution; also available as an injection

What is Dicaltrol?

Dicaltrol is a brand name medication whose active ingredient is calcitriol. Calcitriol is the synthetically produced, biologically most active form of Vitamin D3 (1,25-dihydroxycholecalciferol). It functions as a secosteroid hormone that plays a crucial role in maintaining the balance of calcium and phosphate in the body, a process known as calcium homeostasis.

Mechanism of Action

Calcitriol works primarily by binding to the Vitamin D Receptor (VDR), which is expressed in various tissues, including the intestines, bone, kidneys, and parathyroid glands. By activating these receptors, calcitriol:

  • Promotes the absorption of dietary calcium and phosphate from the gastrointestinal tract.
  • Increases the reabsorption of calcium in the kidneys, helping to reduce its loss in urine.
  • Acts on bone cells to stimulate the release of calcium from the skeleton, particularly when blood calcium levels are low.

This overall action helps to increase and maintain sufficient serum calcium levels.

Clinical Use

Dicaltrol (calcitriol) is commonly prescribed to treat conditions related to impaired calcium metabolism and bone disease, particularly in patients with kidney problems, where the natural production of active Vitamin D is often compromised. Key indications include the management of secondary hyperparathyroidism and associated metabolic bone disease in patients with moderate to severe chronic kidney disease, and the treatment of hypocalcemia (low calcium levels) in patients undergoing chronic renal dialysis. It may also be used for other hypocalcemic disorders like hypoparathyroidism.

Regulatory References

  1. Calcitriol - StatPearls - NCBI Bookshelf
  2. Physiology, Parathyroid Hormone - StatPearls - NCBI Bookshelf

What side effects are possible with Dicaltrol?

Possible Side Effects and Safety Information

The safety profile of Dicaltrol (calcitriol) is directly related to its potent effect on the body's mineral balance, with the primary risk documented in regulatory sources being hypercalcemia (high calcium levels). This condition is often classified as a very common adverse reaction, particularly in patients undergoing chronic renal dialysis. The official classification of adverse reactions is organized by System-Organ Class, reflecting effects across multiple body systems.


Adverse Reaction Classification

System-Organ Class Examples of Documented Effects
Metabolism and nutrition Hypercalcemia, hypercalciuria (excess calcium in urine)
Gastrointestinal Nausea, vomiting, abdominal pain, constipation
Nervous system Headache, somnolence, lethargy
Renal and urinary Polyuria (increased urination), nocturia
Skin Rash, pruritus (itching)

Serious Reactions and Safety Constraints

The most clinically significant safety concern is the progression of hypercalcemia, which, if sustained, can lead to chronic consequences such as generalized vascular calcification and nephrocalcinosis (calcification within the kidney). Regulatory documents specify that the product of serum calcium and phosphate (Ca x P) should not be allowed to exceed 70, as exceeding this limit is linked to an increased safety risk.

Official labels also outline specific safety constraints. Dicaltrol is contraindicated in individuals with pre-existing hypercalcemia or known evidence of Vitamin D toxicity. Safety monitoring is highlighted as crucial for specific populations, with chronic renal dialysis patients requiring frequent determination of serum calcium and phosphate levels during the initial phase of treatment.

Overdose and Emergency Response

The official regulatory documents state that Dicaltrol overdose results in progressive hypercalcemia, a defining physiological condition caused by an excess of the active ingredient, calcitriol. This condition and the associated mineral imbalances (hypercalciuria and hyperphosphatemia) are the basis of the overdose profile. Manifestations documented in the regulatory labeling may include early, acute symptoms such as dry mouth, metallic taste, nausea, vomiting, and somnolence. Chronic or advanced overdose is associated with symptoms such as polyuria, polydipsia, weight loss, and photophobia.

Progressive hypercalcemia from overdose may be severe enough to require emergency medical attention due to the risk of serious complications. These risks are officially documented to include generalized vascular calcification, nephrocalcinosis, and the precipitation of cardiac arrhythmias, especially in patients receiving digitalis. Immediate actions mandated by regulatory sources include discontinuing the medicine and all calcium supplements, and procedures such as gastric lavage may be described for acute situations. No specific antidote is known; therefore, treatment focuses on supportive measures and managing mineral balance. Repeated serum calcium determinations are necessary, and monitoring must ensure the serum calcium times phosphate product does not exceed 70 mg^2/ dL^2, as specified in regulatory guidance.

Therapeutic Uses of Dicaltrol

What Dicaltrol Treats: Main Uses and Benefits

Dicaltrol is commonly used to help manage systemic imbalances involving calcium and phosphate, which is considered relevant for skeletal support. It is applied when appropriate in situations involving certain distressing symptoms.

This medication plays a role in managing conditions such as secondary hyperparathyroidism, metabolic bone disease (renal osteodystrophy) in patients with chronic kidney failure, and hypocalcemia (low calcium levels), often seen in individuals undergoing chronic dialysis or with hypoparathyroidism.

It provides supportive relief by helping to manage symptoms of increased neurological or muscular activity that accompany mineral deficiency, such as muscle cramping and tingling. This supports patients during difficult episodes by helping them cope more steadily with symptom fluctuations.


Quick Fact: Support for Skeletal and Neuromuscular Symptoms

  • Targeted Conditions: Metabolic Bone Disease (Renal Osteodystrophy), Hypoparathyroidism, and Secondary Hyperparathyroidism.
  • Key Benefit: Assists with maintaining functional stability and contributes to improved comfort when symptoms related to systemic imbalance are present.
  • Clinical Context: Applied in clinical settings that involve acute or unstable symptom patterns, especially in advanced chronic kidney disease.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The following is a summary of population eligibility and restrictions for Dicaltrol (calcitriol), as documented in authoritative government sources (e.g., FDA and EMA).


Populations For Whom Use is Established

  • Adult Patients: Approved for use in the management of hypocalcemia linked to chronic renal dialysis, moderate to severe chronic renal failure (pre-dialysis, CrCl 15 to 55 mL/min), and specific forms of hypoparathyroidism.
  • Pediatric Patients (ge 1 year): Use is generally established for these conditions, although some regulatory bodies state that use of oral capsules is not sufficiently investigated or is not established in children under one year.

Populations For Whom Use is Prohibited (Contraindications)

  • Patients with documented hypercalcemia (high calcium levels in the blood).
  • Patients with clear evidence of vitamin D toxicity or overdose.
  • Individuals with a known hypersensitivity or allergy to calcitriol or any of the product's excipients.

Conditional Use and Regulatory Status

Area of Restriction Regulatory Classification
Pregnancy Category C status; requires close monitoring of serum calcium levels.
Lactation Calcitriol transfers into breast milk; requires monitoring of both mother and infant.
Co-existing Treatment Use with digitalis (digoxin) requires extreme care due to the risk of cardiac arrhythmias.
Hepatic Function Studies have not been conducted; use requires caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Dicaltrol (calcitriol) defines its interaction profile based on its function as an active vitamin D metabolite and its effects on calcium and phosphate regulation.

Classification Feature Details (Based on Official Documents)
Interactions Prohibited (Contraindicated) The co-administration of Dicaltrol is formally prohibited with other Vitamin D metabolites and phosphate preparations due to the risk of additive effects, including hypercalcemia and ectopic calcification.
Pharmacodynamic Additive Effects Thiazide diuretics and calcium supplements are associated with a documented increase in the risk of hypercalcemia because of additive effects on calcium levels. Hypercalcemia, when present, can potentiate the risk of digitalis (Digoxin) toxicity.
Exposure-Altering Interactions Anticonvulsants such as phenobarbital and phenytoin may reduce calcitriol's systemic exposure by inducing metabolic enzymes. Conversely, substances that bind to bile acids, such as Cholestyramine, may impair intestinal absorption, which requires a mandatory timing separation to mitigate the reduced exposure risk.
Population-Specific Risk The official label highlights a specific risk of hypermagnesemia when combining Dicaltrol with magnesium-containing antacids, which is particularly relevant in patients with chronic renal failure due to impaired magnesium clearance.

These interaction statements define the need to avoid combinations that excessively raise mineral levels or significantly alter the amount of active calcitriol available to the body.

Mechanism of Action

Dicaltrol, the active form of vitamin D (calcitriol or 1,25-( OH)2 D3), functions as an agonist of the Vitamin D Receptor (VDR), a nuclear transcription factor. The lipophilic molecule is transported in plasma primarily bound to the vitamin D binding protein (DBP) and enters target cells, including those in the intestine, bone, kidney, and parathyroid gland.

Upon binding to the cytosolic VDR, the ligand-receptor complex translocates to the cell nucleus, where it dimerizes with the Retinoid X Receptor (RXR). This heterodimer binds to specific DNA sequences called Vitamin D Response Elements (VDREs) in the promoter region of target genes. This interaction modulates the transcription of genes encoding proteins responsible for calcium and phosphate homeostasis, such as the calcium-binding protein in intestinal epithelial cells.

Downstream consequences include increased gene expression that facilitates the absorption of calcium and phosphate from the gastrointestinal tract and promotes renal tubular reabsorption of calcium. Furthermore, VDR activation in osteoblasts stimulates the release of RANKL, which acts on osteoclasts to modulate bone resorption. The overall systemic consequence is an elevation in serum calcium and phosphate concentrations.

Dosage and Administration Information

How Dicaltrol Is Used

Dicaltrol (calcitriol) is administered through specific patterns to manage systemic calcium and phosphate imbalances, primarily in patients with chronic kidney failure or hypoparathyroidism. The medication is available as both an oral capsule or solution for at-home use and as an intravenous (IV) injection for administration in clinical settings, such as during hemodialysis.


Administration and Dosing Principles

Treatment regimens are based on careful titration, starting with a low dose. For most adult oral uses, the initial starting dose is typically 0.25 mcg daily or every other day. For IV use in patients on dialysis, the initial dose is generally 1 mcg to 2 mcg administered three times weekly at the end of the dialysis session.


Conditions of Use

Usage Condition Official Instruction Principle
Dose Adjustment Dose increments are made at specified, long intervals (e.g., 4 to 8 weeks for oral use).
Ingestion Oral forms can be taken with or without food, but capsules must be swallowed whole with water.
Concomitant Therapy The administration of Dicaltrol requires adequate daily intake of calcium (typically 600 mg to 800 mg or more) to ensure proper functioning.
Adjustment Principle Frequent monitoring of serum calcium (e.g., at least twice weekly during initial titration) is mandatory. The dose must be held or reduced immediately if calcium levels rise above the specified threshold.

These protocols establish the standardized, monitored approach required for the use of Dicaltrol, ensuring the regimen remains aligned with the official labeled instructions.

Recent Clinical Evidence

Dicaltrol: Recent Clinical Evidence

Research evidence / Overview of studies

Preclinical research evaluated the drug's studied pathway in laboratory settings. Studies have explored the use of Dicaltrol in people with refractory X-disease.


Phase 3 Trial Data: Findings related to symptom relief

The main phase 3, double-blind, randomized controlled trial (RCT) evaluated whether the drug was associated with a change in symptom scores, compared with placebo at 12 weeks. Research examined whether the changes in disease activity were maintained for up to one year. Analyses of the RCT indicated that a subset of patients receiving a higher dose showed differences in response rates.


Combination Studies: Exploring Combined Therapy

Research evaluated whether combining Dicaltrol with standard therapy was associated with differences in pain and inflammation outcomes compared with either treatment alone. Studies also examined whether the combination was associated with changes in the overall quality of life.


Long-term Safety Data

Long-term safety studies evaluated the incidence of serious adverse events (SAEs) and reported the findings. While no definitive causal link has been established, research explored whether the use of the drug was associated with changes in the incidence of disease flares in the long term.

Key Studies & References National Guidelines for the Management of Refractory X-Disease: Recommendations on Targeted Inhibitors and Combination Therapy

Frequently Asked Questions (FAQ)

Common questions about Dicaltrol (FAQ)


Q: How quickly does Dicaltrol typically start to have an effect?

According to official prescribing information, after taking Dicaltrol by mouth, the concentration of the active ingredient in the bloodstream typically reaches its highest level within 3 to 6 hours. However, the overall therapeutic benefit is often managed as a long-term treatment, and the main pharmacologic activity from a single dose is generally expected to last about 3 to 5 days.


Q: Can older adults safely use Dicaltrol?

Regulatory documents indicate that clinical studies haven't included enough older adults (aged 65 and over) to fully assess if they respond differently than younger patients. Because older adults are more likely to have other medical conditions or decreased organ function, official guidance describes that the dose selection in older adults may be approached cautiously and may start at the lower dosage ranges.


Q: What are the rules about taking Dicaltrol during pregnancy?

Dicaltrol is classified as Pregnancy Category C by the FDA, which means animal studies showed potential risk but human studies are lacking. Official information states that it should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Close monitoring of the pregnant person's serum calcium levels is required.


Q: What are the restrictions for women who are breastfeeding and want to use Dicaltrol?

The active ingredient in Dicaltrol is known to pass into breast milk. Due to the potential for adverse effects on the infant’s calcium balance, official documents specify that monitoring of both the mother and the infant is necessary if the medication is used while breastfeeding.


Q: What are the general rules for taking Dicaltrol with meals?

Official administration instructions specify that the oral capsule or solution form of Dicaltrol can generally be taken with or without food. The regulatory documents state that capsules are intended to be swallowed whole with water.


Q: Can Dicaltrol be used by individuals with liver function issues?

The liver plays a role in the metabolism and elimination of the active ingredient. Official regulatory information advises that use requires caution in patients with hepatic (liver) impairment, as this condition could alter the drug's activity in the body. Studies in this specific population have not been conducted.


Q: How does the body eliminate Dicaltrol after it's taken?

After it is absorbed, Dicaltrol's active ingredient is broken down (metabolized) through specific enzyme pathways in the body. The main resulting product of this process is a non-active metabolite known as calcitroic acid.


Q: Can Dicaltrol be taken by someone with kidney concerns?

The drug is prescribed to manage specific metabolic issues that often arise from kidney concerns. Its authorized uses include treating low calcium and metabolic bone disease in patients with moderate to severe chronic renal failure and those undergoing dialysis.


Q: Are there any common foods or drinks that should be avoided while taking Dicaltrol?

Official documents describe that consuming excessive amounts of foods and supplements containing calcium, phosphate, and vitamin D could increase the risk of side effects. Separately, some sources indicate that grapefruit and grapefruit juice have the potential to alter the drug's effects and blood levels.


Q: Does Dicaltrol cause weight changes?

Weight changes are not listed as a common or major side effect of Dicaltrol in official safety documents. However, weight loss is listed as one of the possible late-stage signs associated with an overdose or excessive long-term vitamin D intake.


Q: Is Dicaltrol considered a long-term treatment or is it for short use?

Dicaltrol is typically used as a long-term therapy for chronic conditions, such as hypocalcemia associated with chronic renal failure or hypoparathyroidism. Treatment is often continued over long periods, with the dosage adjusted at intervals of several weeks to maintain mineral balance.


Q: What happens if I miss a scheduled dose of Dicaltrol?

Official drug information contains specific directions for managing a missed dose. These directions specify that generally, the next dose should be taken at the regularly scheduled time, and taking a double dose to make up for a missed dose is not advised. This information is detailed in the administration section of the prescribing label.


Q: Is Dicaltrol a type of vitamin or a hormone?

Dicaltrol is the brand name for calcitriol, which is both the biologically active form of Vitamin D3 and a compound that functions in the body as a secosteroid hormone. This dual nature enables it to regulate mineral balance across multiple body systems.


Q: Are there any lab tests required before starting Dicaltrol?

Official guidelines do not explicitly list pre-screening tests, but the drug is contraindicated (should not be used) in patients with pre-existing high calcium levels or Vitamin D toxicity. This contraindication implies that blood levels of calcium and potentially other markers should be evaluated prior to treatment.


Q: Can Dicaltrol affect my ability to drive or operate machinery?

Regulatory documents list central nervous system (CNS) effects such as somnolence (drowsiness) and lethargy (lack of energy) as possible side effects. The presence of these effects may pose a risk to activities that require high levels of concentration, such as driving or operating machinery.


Q: Does Dicaltrol have the potential to interact with herbal supplements?

Official precautions state that a healthcare provider should be aware of all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products being taken. This is necessary to allow for the assessment of potential interaction risks or the need for increased monitoring.


Q: Is it normal to feel slightly nauseous after starting Dicaltrol?

Nausea is listed in official documents as a documented common gastrointestinal side effect of Dicaltrol. It is also listed as one of the early signs that may indicate excessive vitamin D intake, which is why it may require evaluation by a healthcare professional.


Q: What makes Dicaltrol different from other similar treatments?

Dicaltrol's active ingredient, calcitriol, is distinguished because it is the ready-to-use active compound and the most biologically potent form of Vitamin D. This means it can function directly as a hormone and does not require further processing by the kidney or liver to become active, unlike other forms of Vitamin D.


Q: Has Dicaltrol been studied in children?

Yes, regulatory documents include established information on the use of Dicaltrol in pediatric patients aged 1 year and older for conditions such as hypoparathyroidism. Official prescribing information provides dosage guidelines and use recommendations specifically for this younger population.


Q: What kind of monitoring is typically done when a person is on Dicaltrol?

Frequent monitoring of blood levels is mandatory. Official guidance requires monitoring of serum calcium and phosphate levels, typically at least twice a week during initial therapy and after any dosage adjustments. The product of serum calcium and phosphate (Ca x P) must also be monitored to ensure it remains below a specified safety limit.


Q: Are there specific symptoms that require immediate medical attention while on Dicaltrol?

Signs of a severe allergic reaction (such as difficulty breathing or swelling) are documented as requiring immediate attention. Symptoms of high calcium levels (hypercalcemia), which include nausea, vomiting, increased thirst, muscle weakness, or bone pain, are also documented as requiring immediate medical evaluation.


Q: Does Dicaltrol affect sleep or energy levels?

Official adverse effects sections list potential effects on the nervous system, including somnolence (drowsiness) and lethargy (lack of energy). These are also cited as early signs that may occur if the level of the active ingredient is too high.


Q: What happens if a person takes too much Dicaltrol?

Taking too much Dicaltrol can lead to hypercalcemia (high calcium levels) and symptoms of Vitamin D toxicity. Official information states that the management of an overdose includes immediate discontinuation of the drug and addressing the resulting hypercalcemia under medical supervision.


Q: Is it safe to drink alcohol in moderation while using Dicaltrol?

Official drug labels do not generally list alcohol as a direct interaction. However, given that alcohol can affect overall health and hydration, which are important factors in mineral balance management, it is necessary to discuss alcohol consumption with a healthcare provider.


Q: Can I stop taking Dicaltrol suddenly without consulting a healthcare provider?

Due to Dicaltrol's potent effects on calcium and phosphate regulation, regulatory information indicates that abrupt cessation of the medication is generally not advised. Any changes to the dosage or discontinuation must be made under medical supervision and guided by frequent blood level monitoring.


Q: Are there generic versions of Dicaltrol available?

Yes, the active ingredient in Dicaltrol, calcitriol, is available in the United States and other markets as a generic prescription drug. These generic versions are listed in regulatory databases as therapeutically equivalent to the brand-name product.


Q: What should I do if I experience a persistent side effect from Dicaltrol?

Official patient information describes that persistent or concerning symptoms, particularly those listed as side effects (such as vomiting, increased thirst, or weakness), may require immediate evaluation and advice from a healthcare provider.


Q: Are there any known long-term effects associated with Dicaltrol?

The most clinically significant long-term risk noted in regulatory documents is related to sustained hypercalcemia (high calcium levels) that is not controlled. This condition can lead to chronic consequences such as generalized vascular calcification (hardening of blood vessels) and nephrocalcinosis (calcification within the kidney).


Q: Is Dicaltrol suitable for vegetarian or vegan diets?

While the active ingredient is synthetically produced, the excipients (inactive ingredients) in different product formulations, such as the capsule shell, may sometimes be derived from animal sources (like gelatin). Suitability for vegetarian or vegan diets depends entirely on the specific excipient list of the product being used.


Q: Is Dicaltrol a medication that requires specialized handling?

Yes, official instructions specify that the oral product is sensitive to degradation and must be stored in its original, tightly closed container, protected from light and moisture. The injectable form also has specific preparation and administration protocols that must be followed by professionals.


Q: Can Dicaltrol be used to treat a deficiency?

Dicaltrol is the active form of Vitamin D, and its authorized uses focus on regulating mineral balance and treating bone disease, particularly in conditions where the body cannot activate Vitamin D normally (like kidney failure). It is not the typical initial treatment for a general Vitamin D deficiency in otherwise healthy individuals.

How should Dicaltrol be stored and disposed of?

How to Store and Dispose of Dicaltrol?

Dicaltrol (calcitriol) must be stored under specific environmental and packaging conditions to maintain its stability and effectiveness, as mandated by regulatory documents.

Storage Requirements

The medication must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F to 77 F). The product must be protected from light and moisture and should be kept in its original, tightly closed, light-resistant container. This is required because calcitriol is sensitive to degradation from light and air.

All medication must be kept out of the sight and reach of children.

Disposal

Disposal of unused or expired Dicaltrol should be carried out according to local regulations or via an approved drug take-back program. The product should not be disposed of via household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dicaltrol found in:

A-Z Index: